Thymosin Alpha-1 is a naturally occurring thymic peptide that plays a central role in immune system regulation. It is one of the most clinically validated peptides in existence, with regulatory approval in over 35 countries.
Research Applications
Immune modulation, viral hepatitis treatment, vaccine adjuvant research, cancer immunotherapy combinations, and immune restoration in immunocompromised models.
Dosage Information (Research Use)
Approved clinical dose: 1.6 mg subcutaneously twice weekly. Research protocols vary from 1-3 mg, 2-3 times per week. Research use only in the US.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Approximately 2 hours, but immunomodulatory effects persist for days due to T-cell programming and cytokine cascade effects.
Reported Observations in Literature
Excellent safety profile across decades of clinical use. Injection site reactions are the most commonly reported adverse effect. No significant systemic toxicity documented.
Key Research References
- Garaci E. “Thymosin alpha1: from bench to bedside.” Ann N Y Acad Sci. 2007
- Romani L, et al. “Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance.” Ann N Y Acad Sci. 2012